Ceryvyn Therapeutics Limited

As of December 31, 2024, Ceryvyn Therapeutics Ltd. carries a market capitalization of 519.48M, placing it among publicly traded companies globally. Its enterprise value stands at 544.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ceryvyn Therapeutics Ltd.'s next confirmed earnings release is scheduled for February 23, 2027.

As of December 31, 2024, Ceryvyn Therapeutics Ltd. has 1.23B shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Ceryvyn Therapeutics Ltd. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

As of the close on June 8, 2026, Ceryvyn Therapeutics Ltd.'s stock has declined approximately 97.73% over the past 52 weeks.

As of December 31, 2024, Ceryvyn Therapeutics Ltd. holds 131.33M in cash and equivalents against 156.54M in total debt, resulting in a net debt position of 25.18M. Total book value stands at -167.95M, with working capital of 52.14M providing operational flexibility.

These figures cover the twelve months ended December 31, 2024.

These figures cover the twelve months ended December 31, 2024. Total shareholder yield is negative at -6.66, meaning Ceryvyn Therapeutics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ceryvyn Therapeutics Ltd.'s most recent stock split took place on June 14, 2024 with a 35:38 split ratio.